Retraction: miR-338-3p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2 (International Journal of Oncology (2015) 46 (2277-2285) DOI: 10.3892/ijo.2015.2929);miR-338-3p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2

International Journal of Oncology

Volumn 46, Issue 5, 2015, Pages 2277-2285

  Wen, Chunyan ^a   Liu, Xiaojun ^a   Ma, Hongxi ^b   Zhang, Wenjie ^a   Li, Haifeng ^b  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

miR 338 3p; Ovarian cancer; Ovarian epithelial carcinoma; Pi3K AKT pathway; Runx2

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; MICRORNA; MICRORNA 338 3P; PROTEIN KINASE B; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; MIRN338 MICRORNA, HUMAN; RUNX2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER INHIBITION; CANCER TISSUE; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; OVARIAN EPITHELIAL CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ADULT; AGED; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MIDDLE AGED; NEOPLASM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUNEL ASSAY; WESTERN BLOTTING; XENOGRAFT;

ADULT; AGED; ANIMALS; BLOTTING, WESTERN; CELL SURVIVAL; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84925435315     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2021.5237     Document Type: Erratum

References (39)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Lengyel E: Ovarian cancer development and metastasis. Am J Pathol 177: 1053-1064, 2010.
3. Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10: 211-224, 2013.
4. He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004.
5. Erhard F, Haas J, Lieber D, Malterer G, Jaskiewicz L, Zavolan M, Dölken L and Zimmer R: Widespread context dependency of microRNA-mediated regulation. Genome Res 24: 906-919, 2014.
6. Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11: 597-610, 2010.
7. Tong AW and Nemunaitis J: Modulation of miRNA activity in human cancer: A new paradigm for cancer gene therapy? Cancer Gene Ther 15: 341-355, 2008.
8. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
9. Jovanovic M and Hengartner MO: miRNAs and apoptosis: RNAs to die for. Oncogene 25: 6176-6187, 2006.
10. Stevanato L and Sinden JD: The effects of microRNAs on human neural stem cell differentiation in two- and three-dimensional cultures. Stem Cell Res Ther 5: 49, 2014.
11. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
12. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
13. Nam EJ, Yoon H, Kim SW, et al: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-2695, 2008.
14. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007.
15. Li C, Feng Y, Coukos G and Zhang L: Therapeutic microRNA strategies in human cancer. AAPS J 11: 747-757, 2009.
16. Huang XH, Chen JS, Wang Q, Chen XL, Wen L, Chen LZ, Bi J, Zhang LJ, Su Q and Zeng WT: miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol 225: 463-472, 2011.
17. Fu X, Tan D, Hou Z, Hu Z, Liu G, Ouyang Y and Liu F: The effect of miR-338-3p on HBx deletion-mutant (HBx-d382) mediated liver-cell proliferation through CyclinD1 regulation. PLoS One 7: e43204, 2012.
18. Chen X, Pan M, Han L, Lu H, Hao X and Dong Q: miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett 587: 3729-3737, 2013.
19. Caramuta S, Egyházi S, Rodolfo M, Witten D, Hansson J, Larsson C and Lui WO: MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 130: 2062-2070, 2010.
20. Li P, Chen X, Su L, Li C, Zhi Q, Yu B, Sheng H, Wang J, Feng R, Cai Q, et al: Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One 8: e66782, 2013.
21. Guo B, Liu L, Yao J, Ma R, Chang D, Li Z, Song T and Huang C: miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a. Mol Cancer Res 12: 313-321, 2014.
22. Sun K, Su G, Deng H, Dong J, Lei S and Li G: Relationship between miRNA-338-3p expression and progression and prognosis of human colorectal carcinoma. Chin Med J (Engl) 127: 1884-1890, 2014.
23. Sun K, Deng HJ, Lei ST, Dong JQ and Li GX: miRNA-338-3p suppresses cell growth of human colorectal carcinoma by targeting smoothened. World J Gastroenterol 19: 2197-2207, 2013.
24. Zhang S, Lu Z, Unruh AK, et al: Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res: Oct 10, 2014 (Epub ahead of print). pii: molcanres.0424.2014.
25. Kinose Y, Sawada K, Nakamura K and Kimura T: The role of microRNAs in ovarian cancer. BioMed Res Int 2014: 249393, 2014.
26. Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S and Zhang Y: MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS One 9: e115565, 2014.
27. Li W, Xu S, Lin S and Zhao W: Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. J Biomed Biotechnol 2012: 456534, 2012.
28. Sun Q, Liu H, Lin H, Yuan G, Zhang L and Chen Z: MicroRNA-338-3p promotes differentiation of mDPC6T into odontoblast-like cells by targeting Runx2. Mol Cell Biochem 377: 143-149, 2013.
29. Liu H, Sun Q, Wan C, Li L, Zhang L and Chen Z: MicroRNA-338-3p regulates osteogenic differentiation of mouse bone marrow stromal stem cells by targeting Runx2 and Fgfr2. J Cell Physiol 229: 1494-1502, 2014.
30. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, et al: Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764, 1997.
31. Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T, Watanabe M, Inoue S, Ishida T, Ohuchi N, et al: Runx2 in human breast carcinoma: Its potential roles in cancer progression. Cancer Sci 101: 2670-2675, 2010.
32. Brubaker KD, Vessella RL, Brown LG and Corey E: Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 56: 13-22, 2003.
33. Li H, Zhou RJ, Zhang GQ and Xu JP: Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: A 5-year follow-up study. Tumour Biol 34: 1807-1812, 2013.
34. Martin JW, Zielenska M, Stein GS, van Wijnen AJ and Squire JA: The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011: 282745, 2011.
35. Niu DF, Kondo T, Nakazawa T, Oishi N, Kawasaki T, Mochizuki K, Yamane T and Katoh R: Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. Lab Invest 92: 1181-1190, 2012.
36. Kayed H, Jiang X, Keleg S, Jesnowski R, Giese T, Berger MR, Esposito I, Löhr M, Friess H and Kleeff J: Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer 97: 1106-1115, 2007.
37. Wang ZQ, Keita M, Bachvarova M, Gobeil S, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Trinh XB, et al: Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. PLoS One 8: e74384, 2013.
38. Tandon M, Chen Z and Pratap J: Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells. Breast Cancer Res 16: R16, 2014.
39. Tandon M, Chen Z and Pratap J: Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells. J Cell Biochem 115: 2208-2217, 2014.